BM-306 is under clinical development by Notitia Biotechnologies and currently in Phase I for Diabetic Nephropathy. According to GlobalData, Phase I drugs for Diabetic Nephropathy have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BM-306’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NBTBM-306 is under development for the treatment of early/end-stage diabetic kidney disease (DKD). It is a consortia of bacteria developed based on foundation guild microbiome platform.
Notitia Biotechnologies overview
Notitia Biotechnologies is a biotechnology company that creates a platform for the study and discovery of microbiome data using a novel approach. The company is Headquartered in United States.
For a complete picture of BM-306’s drug-specific PTSR and LoA scores, buy the report here.